GlassScriptPhysician profile
Amandeep Kaur
NPI 1245753243
$2,448.38
in general payments reported to CMS, 2019-2025
21 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $274 · 2022: $1,104 · 2023: $909 · 2024: $15.16 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $910 · Consulting Fee: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.49 |
| Consulting Fee | $159.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $266.04 | 2022-2025 | Datroway, Brilinta |
| Merck Sharp & Dohme LLC | $239.28 | 2021-2024 | Keytruda, Lynparza |
| Incyte Corporation | $238.13 | 2022 | |
| Octapharma USA, INC. | $206.71 | 2022-2023 | Nuwiq |
| Bayer Healthcare Pharmaceuticals INC. | $206.36 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $181.10 | 2022-2023 | |
| Glaxosmithkline, LLC. | $142.93 | 2022 | |
| Janssen Biotech, INC. | $138.62 | 2022 | |
| Gilead Sciences, INC. | $119.85 | 2023 | Trodelvy |
| Adaptive Biotechnologies Corporation | $107.25 | 2021-2025 | Clonoseq |
| Seagen INC. | $101.11 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $99.22 | 2021-2023 | Libtayo |
| Eisai INC. | $85.31 | 2022-2023 | |
| Beigene USA, INC. | $65.48 | 2023 | Brukinsa |
| Amgen INC. | $60.56 | 2022-2023 | Lumakras |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $56.56 | 2022 | |
| Stemline Therapeutics INC. | $36.68 | 2023 | Orserdu |
| Pfizer INC. | $27.62 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.50 | 2023 | Gilotrif |
| Abbvie INC. | $23.57 | 2023 | |
| Array Biopharma INC | $18.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amandeep Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.